Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Spero Therapeutics, Inc.
Bear Case (25th pct.)
-29.3% vs price
Base Case (Median)
-21.1% vs price
Bull Case (75th pct.)
13.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.88 | -26.6% | High (40%) |
| PE Comparable | $3.14 | 22.8% | Medium (25%) |
| Graham Number | $1.79 | -30.0% | Medium (40%) |
| EV/EBITDA | $2.17 | -15.3% | Medium (20%) |
| EV/FCF | $7.40 | 189.1% | Medium (20%) |
| Earnings Power Value | $1.47 | -42.4% | Medium (50%) |
Based on 6 out of 7 methods, SPRO appears fairly valued at the current price of $2.56. The base case fair value of $2.02 implies 21.1% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.